Background An exuberant and dysregulated inflammatory response contributes to the
development and progression of cardiovascular diseases (CVDs). Methods This narrative …

The prevalence and severity of metabolic dysfunction associated steatotic liver disease
(MASLD) are increasing. Physicians who treat patients with MASLD may acknowledge the …

Coronary artery disease (CAD) covers a wide spectrum from persons who are asymptomatic
to those presenting with acute coronary syndromes (ACS) and sudden cardiac death …

Background Guidelines recommend low-dose colchicine for secondary prevention in
cardiovascular disease, but uncertainty remains concerning its efficacy for stroke, efficacy in …

Inflammation plays an important role in the development and progression of cardiovascular
diseases (CVDs). Hypertension and hyperlipidemia are the key risk factors of CVDs and …

The unpredictable nature of new variants of coronavirus 2 (SARS-CoV-2)—highly
transmissible and some with vaccine-resistance, have led to an increased need for feasible …

Aims Recent evidence from randomized trials demonstrates that colchicine can reduce the
risk of major adverse cardiovascular events (MACE) in patients with coronary artery disease …

Colchicine is an anti-inflammatory medication, classically used to treat a wide spectrum of
autoimmune diseases. More recently, colchicine has proven itself a key pharmacotherapy in …

Inflammation is a key feature of atherosclerosis. The inflammatory process is involved in all
stages of disease progression, from the early formation of plaque to its instability and …

Several randomized clinical trials have demonstrated the clinical utility of colchicine in the
prevention and management of various cardiovascular conditions, including secondary …